Swiss Medical Weekly (Jul 2025)
Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network
- Max J. Rieger,
- Andreas J. Flammer,
- Sabine Gerull,
- Thomas Pabst,
- Holger W. Auner,
- Kaveh Samii,
- Felicitas Hitz,
- Ulrich Mey,
- Veronika Ballova,
- Raphael Battegay,
- Giorgia Melli,
- Dominik Benz,
- Yakup Yakupoglu,
- Christoph Gräni,
- Regina Schläger,
- Sarah Hugelshofer,
- Annina Studer,
- Luca Oechslin,
- Adam Bakula,
- Thomas M. Suter,
- Julia Leo-Stickelberger,
- Manuela Averiamo,
- Thomas Fehr,
- Hans H. Jung,
- Natallia Laptseva,
- Robert Manka,
- Axel Rüfer,
- Adrian Schmidt,
- Harald Seeger,
- Beat Müllhaupt,
- Simon F. Stämpfli,
- Carmen de Ramon Ortiz,
- Marie Théaudin,
- Bernhard Gerber,
- Rahel Schwotzer
Affiliations
- Max J. Rieger
- University Hospital of Zurich, Department of Medical Oncology and Hematology
- Andreas J. Flammer
- University Heart Center, University Hospital, Zurich, Switzerland
- Sabine Gerull
- Department of Medical Oncology and Hematology, Cantonal Hospital Aarau, Switzerland
- Thomas Pabst
- Department of Oncology, University Hospital Inselspital Bern, Bern, Switzerland
- Holger W. Auner
- Department of Hematology, Lausanne University Hospital, Lausanne, Switzerland
- Kaveh Samii
- Department of Hematology, University Hospital of Geneva, Geneva, Switzerland
- Felicitas Hitz
- Department of Medical Oncology and Hematology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland
- Ulrich Mey
- Department of Oncology and Hematology, Cantonal Hospital Graubünden, Chur, Switzerland
- Veronika Ballova
- Department of Medical Oncology and Hematology, Cantonal Hospital Baden, Baden, Switzerland
- Raphael Battegay
- Department of Hematology, University Hospital Basel, Basel, Switzerland
- Giorgia Melli
- Department of Neurology and Neurodegenerative Diseases Group, Laboratories for Translational Research, Neurocenter of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
- Dominik Benz
- Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
- Yakup Yakupoglu
- Division of Cardiology, Cantonal Hospital Aarau, Switzerland
- Christoph Gräni
- Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland
- Regina Schläger
- Department of Neurology, University Hospital Basel, Basel, Switzerland
- Sarah Hugelshofer
- Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland
- Annina Studer
- Department of Internal Medicine, Clinic for Cardiology and Institute for Radiology and Nuclear medicine, Stadtspital Zurich Triemli, Zurich, Switzerland
- Luca Oechslin
- Hirlsanden Heart Center, Zurich, Switzerland
- Adam Bakula
- Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland
- Thomas M. Suter
- Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Switzerland
- Julia Leo-Stickelberger
- Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
- Manuela Averiamo
- Cardiocentro Ticino, Lugano, Switzerland
- Thomas Fehr
- Department of Internal Medicine, Cantonal Hospital Graubünden, Chur, Switzerland
- Hans H. Jung
- Department of Neurology, University Hospital and University Zurich, Zurich, Switzerland
- Natallia Laptseva
- University Heart Center, University Hospital, Zurich, Switzerland
- Robert Manka
- University Heart Center, University Hospital, Zurich, Switzerland
- Axel Rüfer
- Department of Hematology, Cantonal Hospital Lucerne, Lucerne, Switzerland
- Adrian Schmidt
- Department of Internal Medicine, Clinic for Medical Oncology and Hematology, Stadtspital Zurich Triemli, Zurich, Switzerland
- Harald Seeger
- Institute for Nephrology and Dialysis, Cantonal Hospital Baden, Baden, Switzerland
- Beat Müllhaupt
- Department of Gastroenterology and Hepatology, University Hospital Zurich
- Simon F. Stämpfli
- Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland
- Carmen de Ramon Ortiz
- Department of Hematology, University Hospital of Geneva, Geneva, Switzerland
- Marie Théaudin
- Department of Clinical Neurosciences, Service of Neurology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
- Bernhard Gerber
- Division of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
- Rahel Schwotzer
- Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
- DOI
- https://doi.org/10.57187/s.4219
- Journal volume & issue
-
Vol. 155,
no. 7
Abstract
Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous “therapeutic recommendations” while the previous “diagnostic recommendations” remain valid.
